BenevolentAI CEO and leadership

Baroness Joanna Shields is a Board Member at WEPROTECT GLOBAL ALLIANCE LTD, Chief Executive Officer/Exec Dir at BenevolentAI, and Founder at WEPROTECT GLOBAL ALLIANCE LTD. She has worked as Managing Director:Europe at GOOGLE INC., VP:Global Sales at EFI (Electronics For Imaging Inc.), and Minister:Internet Security & Safety at REO. Baroness works or has worked as Chief Executive Officer at Bebo.

Ivan Griffin is Vice President of Business Development at BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, spin-out company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he completed a year’s post-doctoral research.

Mr. Brent Gutekunst co-founded BenevolentAI Limited in 2013 and also serves as its Chief Development Officer. Mr. Gutekunst is the founder of Stratified Medical, Inc. Previously, he founded TouchDx in 2009. Prior to TouchDx, he founded E-Auction. He also founded Collectors Universe and after merging with leading firms in the collectibles industry completed a successful IPO in collectibles.

Anne has over 20 years experience in Pharmaceutical Drug Discovery. With experience in a number of disease area specific Research Units and clinical project leadership expertise, Anne’s predominant focus over the last |8 years has been on pre-clinical portfolio management, technology investment and the generation of plate based pharmacology and phenotypic data across a wide range of target classes and therapeutic modalities.

Specialities: Team leadership, Business strategy and operations, Drug Discovery, Molecular Pharmacology, Plate based screening, Reagent generation, Genomics, Technology investment, Project Management, Portfolio co-ordination, Performance management, CRO Outsourcing, Clinical project leadership.

Ivan Griffin is Vice President of Business Development at BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, spin-out company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he completed a year’s post-doctoral research.

Mr. Brent Gutekunst co-founded BenevolentAI Limited in 2013 and also serves as its Chief Development Officer. Mr. Gutekunst is the founder of Stratified Medical, Inc. Previously, he founded TouchDx in 2009. Prior to TouchDx, he founded E-Auction. He also founded Collectors Universe and after merging with leading firms in the collectibles industry completed a successful IPO in collectibles.

Baroness Joanna Shields is a Board Member at WEPROTECT GLOBAL ALLIANCE LTD, Chief Executive Officer/Exec Dir at BenevolentAI, and Founder at WEPROTECT GLOBAL ALLIANCE LTD. She has worked as Managing Director:Europe at GOOGLE INC., VP:Global Sales at EFI (Electronics For Imaging Inc.), and Minister:Internet Security & Safety at REO. Baroness works or has worked as Chief Executive Officer at Bebo.

Ivan Griffin is Vice President of Business Development at BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, spin-out company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he completed a year’s post-doctoral research.

Nick joined Benevolent AI as CFO in March 2022 having previously been CFO of Clinigen, a UK AIM listed Global Pharmaceutical and Pharma Services company with over £450m of revenue. Prior to this Nick was an equity analyst covering the European healthcare space for over eight years, first at Investec and then at RBC where he was Managing Director and Head of RBC’s European healthcare equity research team. Nick began his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (‘GSK’) where he completed his accountancy qualification (ACMA) working within GSK’s finance function.